41 results on '"Nisticò, S"'
Search Results
2. Blue light-emitting diodes in hair regrowth: the first prospective study
- Author
-
Lodi, G., Sannino, M., Cannarozzo, G., Giudice, A., Del Duca, E., Tamburi, F., Bennardo, Luigi, and Nisticò, S. P.
- Published
- 2021
- Full Text
- View/download PDF
3. Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study
- Author
-
Talamonti, M, Galluzzo, M, Chiricozzi, A, Quaglino, P, Fabbrocini, G, Gisondi, P, Marzano, A, Potenza, C, Conti, A, Parodi, A, Piaserico, S, Bardazzi, F, Argenziano, G, Rongioletti, F, Stingeni, L, Micali, G, Loconsole, F, Rossi, M, Bongiorno, M, Feliciani, C, Rubegni, P, Amerio, P, Fargnoli, M, Pigatto, P, Savoia, P, Nisticò, S, Giustini, S, Carugno, A, Cannavo’, S, Rech, G, Prignano, F, Offidani, A, Lombardo, M, Zalaudek, I, Bianchi, L, Peris, K, Talamonti, M., Galluzzo, M., Chiricozzi, A., Quaglino, P., Fabbrocini, G., Gisondi, P., Marzano, A. V., Potenza, C., Conti, A., Parodi, A., Piaserico, S., Bardazzi, F., Argenziano, G., Rongioletti, F., Stingeni, L., Micali, G., Loconsole, F., Rossi, M. T., Bongiorno, M. R., Feliciani, C., Rubegni, P., Amerio, P., Fargnoli, M. C., Pigatto, P., Savoia, P., Nisticò, S. P., Giustini, S., Carugno, A., Cannavo’, S. P., Rech, G., Prignano, F., Offidani, A., Lombardo, M., Zalaudek, I., Bianchi, L., Peris, K., Talamonti, M, Galluzzo, M, Chiricozzi, A, Quaglino, P, Fabbrocini, G, Gisondi, P, Marzano, A, Potenza, C, Conti, A, Parodi, A, Piaserico, S, Bardazzi, F, Argenziano, G, Rongioletti, F, Stingeni, L, Micali, G, Loconsole, F, Rossi, M, Bongiorno, M, Feliciani, C, Rubegni, P, Amerio, P, Fargnoli, M, Pigatto, P, Savoia, P, Nisticò, S, Giustini, S, Carugno, A, Cannavo’, S, Rech, G, Prignano, F, Offidani, A, Lombardo, M, Zalaudek, I, Bianchi, L, Peris, K, Talamonti, M., Galluzzo, M., Chiricozzi, A., Quaglino, P., Fabbrocini, G., Gisondi, P., Marzano, A. V., Potenza, C., Conti, A., Parodi, A., Piaserico, S., Bardazzi, F., Argenziano, G., Rongioletti, F., Stingeni, L., Micali, G., Loconsole, F., Rossi, M. T., Bongiorno, M. R., Feliciani, C., Rubegni, P., Amerio, P., Fargnoli, M. C., Pigatto, P., Savoia, P., Nisticò, S. P., Giustini, S., Carugno, A., Cannavo’, S. P., Rech, G., Prignano, F., Offidani, A., Lombardo, M., Zalaudek, I., Bianchi, L., and Peris, K.
- Abstract
Background: The susceptibility of patients with chronic plaque psoriasis and the risks or benefits related to the use of biological therapies for COVID-19 are unknown. Few data about prevalence, clinical course and outcomes of COVID-19 among psoriatic patients were reported. The aims of this study were 1) to assess the prevalence and severity of COVID-19 in psoriatic patients treated with biologic agents during the first phase of the emergency (22 February to 22 April 2020) in Italy, and 2) to report the clinical outcomes of patients who have been exposed to individuals with confirmed SARS-CoV-2 infection. Methods: Patients with moderate-to-severe chronic plaque psoriasis, aged ≥18 years and undergoing treatment with biologic agents as of 22 February 2020, were eligible to be included in PSO-BIO-COVID study. Demographic and clinical characteristics of patients using any biologic for psoriasis treatment between 22 February and 22 April 2020 were registered. Results: A total of 12,807 psoriatic patients were included in the PSO-BIO-COVID study. In this cohort 26 patients (0.2%) had a swab confirmation of SARS-CoV-2 infection. Eleven patients required hospitalization and two died. Conclusion: The incidence of COVID-19 observed in our cohort of psoriatic patients (0.2%) is similar to that seen in the general population (0.31%) in Italy. However, the course of the disease was mild in most patients. Biological therapies may likely lessen ‘cytokine storm’ of COVID-19, which sometimes lead to multiple organ failure, ARDS, and death.
- Published
- 2021
4. CO2 laser in the management of eccrine hidrocystomas: a retrospective study
- Author
-
Fazia, G., primary, Cannarozzo, G., additional, Bennardo, Luigi, additional, and Nisticò, S. P., additional
- Published
- 2021
- Full Text
- View/download PDF
5. CO2 laser in the management of eccrine hidrocystomas: a retrospective study.
- Author
-
Fazia, G., Cannarozzo, G., Bennardo, Luigi, and Nisticò, S. P.
- Published
- 2022
- Full Text
- View/download PDF
6. Tuberculosis in migrants from 106 countries to Italy, 2008-2014
- Author
-
Lanfranco, Fattorini, Alessandro, Mustazzolu, Emanuele, Borroni, Giovanni, Piccaro, Federico, Giannoni, Daniela Maria Cirillo, the Italian Multicentre Study on Resistance to Antituberculosis drugs Group: Ghisetti, V, Mondo, A, Milano, R, Barbui, A, Lorenzetti, P, De Renzi, G, Chirillo, Mg, Molinari, G, Camaggi, A, Carità, Md, Gritti, P, Varnier, O, Senno, E, Mazzola, E, Gesu, G, Cichero, P, Lombardi, A, Libanori, E, De Lorenzo, S, Pinsi, G, Marone, P, Monzillo, V, Matteo, S, Farina, C, Arosio, M, Xxiii, G, Peracchi, M, Manganelli, R, Fabris, C, Scarparo, C, Pedrotti, C, Frizzera, E, Larcher, C, Monte, P, Lombardi, G, Fabio, A, Matteucci, M, Piersimoni, C, Simonetti, Mt, Tortoli, E, Rindi, Laura, Mazzolla, R, Luciano, E, Sanguigni, I, Chiaradonna, P, Tronci, M, Parisi, G, Natili, S, Bordi, E, De Mori, P, Sali, M, Delogu, G, Sanguinetti, M, Russo, C, Coltella, L, Meledandri, M, Ballardini, M, Tomei, G, Santoro, G, Conte, M, Nuzzolese, N, Colonna, C, Buono, L, Sinno, A, Vitullo, E, Costa, D, Grimaldi, A, Di Taranto, A, De Nittis, R, Dodaro, S, Cavalcanti, P, Giraldi, C, Nisticò, S, Di Naso, C, Caddeu, R., Lanfranco Fattorini, Alessandro Mustazzolu, Emanuele Borroni, Giovanni Piccaro, Federico Giannoni, Daniela Maria Cirillo, SMIRA laboratory network: [.., Dal Monte, P., Lombardi, G., and ]
- Subjects
Pulmonary and Respiratory Medicine ,Tuberculosis ,Tuberculosi ,Extensively Drug-Resistant Tuberculosis ,Antitubercular Agents ,Microbial Sensitivity Tests ,Mycobacterium tuberculosi ,World Health Organization ,Russia ,Mycobacterium tuberculosis ,Antitubercular Agent ,03 medical and health sciences ,0302 clinical medicine ,Environmental protection ,Tuberculosis, Multidrug-Resistant ,Humans ,Medicine ,030212 general & internal medicine ,Socioeconomics ,Transients and Migrants ,Geography ,biology ,Microbial Sensitivity Test ,business.industry ,Extensively drug-resistant tuberculosis ,biology.organism_classification ,medicine.disease ,Europe ,Italy ,030228 respiratory system ,Multicenter study ,Extensively Drug-Resistant Tuberculosi ,Africa ,business ,Soviet union ,Human - Abstract
In migrants coming to Italy from 106 countries, MDR-TB was high from the former Soviet Union and low from Africa http://ow.ly/WZDbo
- Published
- 2016
7. Fiscal shocks and the exchange rate in a generalized Redux model
- Author
-
Di Giorgio, Giorgio, Nisticò, S., Traficante, G., and Nisticò, Salvatore
- Published
- 2015
8. Pharmacoeconomy of drugs used in the treatment of actinic keratoses
- Author
-
Nisticò, S, primary, Torchia, V, additional, Gliozzi, M, additional, Bottoni, U, additional, Del Duca, E, additional, and Muscoli, C, additional
- Published
- 2016
- Full Text
- View/download PDF
9. Obesity and kidney disease: Beyond the hyperfiltration
- Author
-
Mascali, A, primary, Franzese, O, additional, Nisticò, S, additional, Campia, U, additional, Lauro, D, additional, Cardillo, C, additional, Di Daniele, N, additional, and Tesauro, M, additional
- Published
- 2016
- Full Text
- View/download PDF
10. Reinterpreting dermoscopic pigment network with reflectance confocal microscopy for identification of melanoma‐specific features.
- Author
-
De Pace, B., Farnetani, F., Losi, A., Ciardo, S., De Carvalho, N., Cesinaro, A. M., Reggiani Bonetti, L., Chester, J., Kaleci, S., Del Duca, E., Nisticò, S. P., Longo, C., and Pellacani, G.
- Subjects
CONFOCAL microscopy ,PIGMENT analysis ,MELANOMA diagnosis ,MELANOMA treatment ,DIFFERENTIAL diagnosis - Abstract
Abstract: Background: Pigment network is an important dermoscopic feature for melanocytic lesions, but alterations in grid line thickness are also observed in melanomas. Objective: To investigate features of thick, thin and mixed pigment networks at dermoscopy and their respective features at reflectance confocal microscopy (RCM) for differential diagnosis, correlated with histology. Methods: All melanocytic lesions with histological diagnosis, evaluated between January 2010 and May 2014, were enrolled and classified according to dermoscopy evaluation of the pigment networks: thin, thick and mixed. Results: Thin network in melanoma was characterized by a honeycombed pattern (P < 0.001), dendritic cells (P < 0.001), atypical ringed pattern (P = 0.035) and structureless area (P = 0.012), whereas round cells (P < 0.001), dendritic cells (P < 0.001) and atypical meshwork pattern (<0.001) characterized thick network in melanoma. Mixed network type in melanoma shared honeycombed (P = 0.049) and typical ringed patterns (P = 0.045) in the thin area and round cells (P < 0.001) and atypical meshwork pattern (P < 0.001) in the thick area. Thin network in nevi was characterized by cobblestone (P < 0.001) and typical ringed patterns (P = 0.035), whereas thick network in nevi showed a typical meshwork pattern (P < 0.001). Mixed nevi shared the same features and patterns, but more frequently with inflammatory infiltrate (P = 0.047). Conclusion: Differential diagnosis between melanocytic lesions (nevi or melanoma) in thin, thick and mixed pigment networks observed at dermoscopy can be assisted by RCM to improve diagnostic accuracy. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
11. Cutaneous manifestations in antiphospholipid syndrome
- Author
-
Caporuscio, S, primary, Sorgi, ML, additional, Nisticò, S, additional, Pranteda, G, additional, Bottoni, U, additional, Carboni, I, additional, and Del Duca, E, additional
- Published
- 2015
- Full Text
- View/download PDF
12. The possible role of glutathione-S-transferase activity in diabetic nephropathy
- Author
-
Tesauro, M, primary, Nisticò, S, additional, Noce, A, additional, Tarantino, A, additional, Marrone, G, additional, Costa, A, additional, Rovella, V, additional, Di Cola, G, additional, Campia, U, additional, Lauro, D, additional, Cardillo, C, additional, and Di Daniele, N, additional
- Published
- 2015
- Full Text
- View/download PDF
13. Use of Dupilumab in 543 Adult Patients With Moderate-to-Severe Atopic Dermatitis: A Multicenter, Retrospective Study
- Author
-
Gabriella Fabbrocini, L Bonzano, Silvia Ferrucci, S Ribero, Simona Tavecchio, Giovanni Pellacani, Steven Paul Nisticò, C Detoraki, Franco Rongioletti, Cataldo Patruno, Paolo Romita, Eustachio Nettis, Viviana Piras, Michela Ortoncelli, M Carbonara, Giulia Calabrese, Danilo Di Bona, E. Di Leo, Luigi Macchia, Caterina Foti, G Argenziano, Maddalena Napolitano, Nettis, E, Ferrucci, S M, Ortoncelli, M, Pellacani, G, Foti, C, Di Leo, E, Patruno, C, Rongioletti, F, Argenziano, G, Macchia, L, Tavecchio, S, Napolitano, M, Ribero, S, Bonzano, L, Romita, P, Di Bona, D, Nisticò, S P, Piras, V, Calabrese, G, Detoraki, C, Carbonara, M, Fabbrocini, G, Nettis, E., Ferrucci, S. M., Ortoncelli, M., Pellacani, G., Foti, C., Di Leo, E., Patruno, C., Rongioletti, F., Argenziano, G., Macchia, L., Tavecchio, S., Napolitano, M., Ribero, S., Bonzano, L., Romita, P., Di Bona, D., Nistico, S. P., Piras, V., Calabrese, G., Detoraki, C., Carbonara, M., and Fabbrocini, G.
- Subjects
Adult ,medicine.medical_specialty ,Immunology ,Population ,Dupilumab ,Antibodies, Monoclonal, Humanized ,Severity of Illness Index ,Dermatitis, Atopic ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,Retrospective Studie ,Interquartile range ,Internal medicine ,Humans ,Immunology and Allergy ,Medicine ,Eosinophilia ,Multicenter real-life study ,education ,Retrospective Studies ,Atopic dermatitis ,education.field_of_study ,business.industry ,Conjunctiviti ,Retrospective cohort study ,Dermatology Life Quality Index ,Immunoglobulin E ,Conjunctivitis ,Atopic dermatiti ,medicine.disease ,Clinical trial ,Treatment Outcome ,030228 respiratory system ,Multicentric real-life study ,medicine.symptom ,business ,Human - Abstract
BACKGROUND Dupilumab has been demonstrated to be an effective treatment for patients with moderate-to-severe atopic dermatitis (AD) in clinical trials. However, evidence of real-world experience with dupilumab in a broader population is limited to date. METHODS Adult patients with moderate-to-severe AD, defined as an Eczema Area Severity Index (EASI) score of 24 or higher, treated with dupilumab at ten Italian academic centers, were included in the study. Physician-reported outcome measures (EASI), patient-reported outcome measures (pruritus and sleep score, Dermatology Life Quality Index, DLQI) and serological markers [immunoglobulin (Ig) E and eosinophil count] after 16 weeks were analyzed. RESULTS We enrolled 543 patients with moderate-to-severe AD. Two patients (0.4%) discontinued treatment. The median ± interquartile percentage change from baseline to 16 weeks of treatment in the EASI score was -87.5±22.0 (p
- Published
- 2022
- Full Text
- View/download PDF
14. Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 pandemic. risk analysis from the PSO-BIO-COVID observational study
- Author
-
Talamonti, Marina, Galluzzo, Marco, Chiricozzi, Andrea, Quaglino, Pietro, Fabbrocini, Gabriella, Gisondi, Paolo, Marzano, Angelo Valerio, Potenza, Concetta, Conti, Andrea, Parodi, Aurora, Piaserico, Stefano, Bardazzi, Federico, Argenziano, Giuseppe, Rongioletti, Franco, Stingeni, Luca, Micali, Giuseppe, Loconsole, Francesco, Rossi, Maria Teresa, Bongiorno, Maria Rita, Feliciani, Claudio, Rubegni, Pietro, Amerio, Paolo, Fargnoli, Maria Concetta, Pigatto, Paolo, Savoia, Paola, Nisticò, Steven Paul, Giustini, Sandra, Carugno, Andrea, Cannavo', Serafinella Patrizia, Rech, Giulia, Prignano, Francesca, Offidani, Annamaria, Lombardo, Maurizio, Zalaudek, Iris, Bianchi, Luca, Peris, Ketty, PSO-BIO-COVID study group, Balestri R, Bernardini N, Belloni Fortini A, Burlando M, Caldarola G, Campione E, Cattaneo A, Dapavo P, Dastoli S, De Simone C, Di Nuzzo S, Diotallevi F, Fierro MT, Franchi C, Esposito M, Foti C, Gambini DM, Gambardella A, Girolomoni G, Giunta A, Guarneri C, Gualdi G, Hansel K, Megna M, Mugheddu C, Musumeci ML, Patrizi A, Pellacani G, Richetta AG, Rosi E, Sacchelli L, Tiberio R, Tilotta G, Trovato E, Venturini M, Vezzoni R, Talamonti, M., Galluzzo, M., Chiricozzi, A., Quaglino, P., Fabbrocini, G., Gisondi, P., Marzano, A. V., Potenza, C., Conti, A., Parodi, A., Piaserico, S., Bardazzi, F., Argenziano, G., Rongioletti, F., Stingeni, L., Micali, G., Loconsole, F., Rossi, M. T., Bongiorno, M. R., Feliciani, C., Rubegni, P., Amerio, P., Fargnoli, M. C., Pigatto, P., Savoia, P., Nistico, S. P., Giustini, S., Carugno, A., Cannavo', S. P., Rech, G., Prignano, F., Offidani, A., Lombardo, M., Zalaudek, I., Bianchi, L., Peris, K., Talamonti, M, Galluzzo, M, Chiricozzi, A, Quaglino, P, Fabbrocini, G, Gisondi, P, Marzano, A, Potenza, C, Conti, A, Parodi, A, Piaserico, S, Bardazzi, F, Argenziano, G, Rongioletti, F, Stingeni, L, Micali, G, Loconsole, F, Rossi, M, Bongiorno, M, Feliciani, C, Rubegni, P, Amerio, P, Fargnoli, M, Pigatto, P, Savoia, P, Nisticò, S, Giustini, S, Carugno, A, Cannavo’, S, Rech, G, Prignano, F, Offidani, A, Lombardo, M, Zalaudek, I, Bianchi, L, Peris, K, Talamonti, Marina, Galluzzo, Marco, Chiricozzi, Andrea, Quaglino, Pietro, Fabbrocini, Gabriella, Gisondi, Paolo, Marzano, Angelo Valerio, Potenza, Concetta, Conti, Andrea, Parodi, Aurora, Piaserico, Stefano, Bardazzi, Federico, Argenziano, Giuseppe, Rongioletti, Franco, Stingeni, Luca, Micali, Giuseppe, Loconsole, Francesco, Rossi, Maria Teresa, Bongiorno, Maria Rita, Feliciani, Claudio, Rubegni, Pietro, Amerio, Paolo, Fargnoli, Maria Concetta, Pigatto, Paolo, Savoia, Paola, Nisticò, Steven Paul, Giustini, Sandra, Carugno, Andrea, Cannavo', Serafinella Patrizia, Rech, Giulia, Prignano, Francesca, Offidani, Annamaria, Lombardo, Maurizio, Zalaudek, Iri, Bianchi, Luca, Peris, Ketty, PSO-BIO-COVID study, Group, Balestri, R, Bernardini, N, Belloni Fortini, A, Burlando, M, Caldarola, G, Campione, E, Cattaneo, A, Dapavo, P, Dastoli, S, De Simone, C, Di Nuzzo, S, Diotallevi, F, Fierro, Mt, Franchi, C, Esposito, M, Foti, C, Gambini, Dm, Gambardella, A, Girolomoni, G, Giunta, A, Guarneri, C, Gualdi, G, Hansel, K, Megna, M, Mugheddu, C, Musumeci, Ml, Patrizi, A, Pellacani, G, Richetta, Ag, Rosi, E, Sacchelli, L, Tiberio, R, Tilotta, G, Trovato, E, Venturini, M, Vezzoni, R, Talamonti M., Galluzzo M., Chiricozzi A., Quaglino P., Fabbrocini G., Gisondi P., Marzano A.V., Potenza C., Conti A., Parodi A., Piaserico S., Bardazzi F., Argenziano G., Rongioletti F., Stingeni L., Micali G., Loconsole F., Rossi M.T., Bongiorno M.R., Feliciani C., Rubegni P., Amerio P., Fargnoli M.C., Pigatto P., Savoia P., Nistico S.P., Giustini S., Carugno A., Cannavo' S.P., Rech G., Prignano F., Offidani A., Lombardo M., Zalaudek I., Bianchi L., and Peris K.
- Subjects
0301 basic medicine ,Male ,Clinical Biochemistry ,Disease ,Cohort Studies ,0302 clinical medicine ,Drug Discovery ,Receptors ,80 and over ,Medicine ,Aged, 80 and over ,education.field_of_study ,Incidence (epidemiology) ,Incidence ,Interleukin-17 ,psoriasis ,Middle Aged ,dermatology ,sars-CoV-2 ,Italy ,biological therapy ,030220 oncology & carcinogenesis ,Cohort ,Biological Product ,COVID-19 ,Female ,Settore MED/35 - MALATTIE CUTANEE E VENEREE ,Adult ,Aged ,Biological Products ,Biological Therapy ,Chronic Disease ,Humans ,Pandemics ,Psoriasis ,Receptors, Interleukin ,Risk Assessment ,Tumor Necrosis Factor-alpha ,Young Adult ,Cohort study ,Human ,medicine.medical_specialty ,Population ,03 medical and health sciences ,Settore MED/35 ,Internal medicine ,education ,Pharmacology ,Psoriasi ,Pandemic ,business.industry ,Biological product ,Interleukin ,medicine.disease ,Clinical trial ,030104 developmental biology ,SARS-CoV-2 ,Cohort Studie ,business - Abstract
Background The susceptibility of patients with chronic plaque psoriasis and the risks or benefits related to the use of biological therapies for COVID-19 are unknown. Few data about prevalence, clinical course and outcomes of COVID-19 among psoriatic patients were reported. The aims of this study were 1) to assess the prevalence and severity of COVID-19 in psoriatic patients treated with biologic agents during the first phase of the emergency (22 February to 22 April 2020) in Italy, and 2) to report the clinical outcomes of patients who have been exposed to individuals with confirmed SARS-CoV-2 infection. Methods Patients with moderate-to-severe chronic plaque psoriasis, aged ≥18 years and undergoing treatment with biologic agents as of 22 February 2020, were eligible to be included in PSO-BIO-COVID study. Demographic and clinical characteristics of patients using any biologic for psoriasis treatment between 22 February and 22 April 2020 were registered. For all confirmed or suspected cases of COVID-19, data about concomitant disease, ongoing therapies, and comorbidities were also reported. Results A total of 12,807 psoriatic patients were included in the PSO-BIO-COVID study. In this cohort twenty-six patients (0.2%) had a swab confirmation of SARS-CoV-2 infection. Eleven patients required hospitalization and two died. 125 of 12807 patients (1.0%) with exposure to a patient with COVID-19 under quarantine or active health surveillance, were reported. Conclusion The incidence of COVID-19 observed in our cohort of psoriatic patients (0.2%) is similar to that seen in the general population (0.31%) in Italy. However, the course of the disease was mild in most patients. Biological therapies may likely lessen "cytokine storm" of COVID-19, which sometimes lead to multiple organ failure, ARDS, and death.
- Published
- 2021
15. Long-term effectiveness of dupilumab up to 52 weeks in atopic dermatitis in 253 adult patients
- Author
-
Silvia Ferrucci, Simona Tavecchio, L Bonzano, Luigi Macchia, Giulia Calabrese, Maddalena Napolitano, Steven Paul Nisticò, Caterina Foti, Aikaterini Detoraki, Katharina Hansel, Giuseppe Argenziano, Giovanni Pellacani, Paolo Romita, Michela Ortoncelli, Franco Rongioletti, Luca Stingeni, E. Di Leo, Gabriella Fabbrocini, Simone Ribero, M Carbonara, Cataldo Patruno, Eustachio Nettis, Viviana Piras, Danilo Di Bona, Nettis, E, Fabbrocini, G, Ortoncelli, M, Pellacani, G, Argenziano, G, Di Leo, E, Patruno, C, Stingeni, L, Foti, C, Rongioletti, F, Macchia, L, Tavecchio, S, Napolitano, M, Ribero, S, Bonzano, L, Calabrese, G, Di Bona, D, Nisticò, S P, Hansel, K, Romita, P, Piras, V, Carbonara, M, Detoraki, A, Ferrucci, S M, Nettis, E., Fabbrocini, G., Ortoncelli, M., Pellacani, G., Argenziano, G., Di Leo, E., Patruno, C., Stingeni, L., Foti, C., Rongioletti, F., Macchia, L., Tavecchio, S., Napolitano, M., Ribero, S., Bonzano, L., Calabrese, G., Di Bona, D., Nistico, S. P., Hansel, K., Romita, P., Piras, V., Carbonara, M., Detoraki, A., and Ferrucci, S. M.
- Subjects
Adult ,medicine.medical_specialty ,Adult patients ,business.industry ,Eczema ,Interleukin ,Dermatology ,Atopic dermatitis ,medicine.disease ,Antibodies, Monoclonal, Humanized ,Dupilumab ,Dermatitis, Atopic ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,Monoclonal ,Medicine ,Humans ,business - Abstract
Dupilumab, an inhibitor of interleukin (IL)-4/13 activity, is a biological agent approved for the treatment of moderate-to-severe atopic dermatitis (AD)1 . Our aim was to assess the long-term effectiveness and safety of dupilumab in a clinical real-life setting.
- Published
- 2021
16. Eczematous eruption during anti‐interleukin 17 treatment of psoriasis: an emerging condition
- Author
-
S. Dastoli, Maddalena Napolitano, Matteo Megna, Nicola Balato, Steven Paul Nisticò, Gabriella Fabbrocini, Cataldo Patruno, Napolitano, M, Megna, M, Fabbrocini, G, Nisticò, S P, Balato, N, Dastoli, S, and Patruno, C
- Subjects
medicine.medical_specialty ,biology ,business.industry ,MEDLINE ,eczematous eruption ,Retrospective cohort study ,Dermatology ,anti-IL-17 agent ,medicine.disease ,Psoriasis ,Monoclonal ,medicine ,biology.protein ,Interleukin 17 ,Young adult ,Antibody ,business ,biologic drug - Abstract
Major advances in psoriasis pathogenesis have resulted in the development of effective new drugs for its treatment. In particular, biologics have revolutionized disease management.1 Tumour necrosis factor (TNF)‐α inhibitors were the first in 2000.1 Thus, adverse cutaneous reactions to their use have been extensively investigated.2 However, the anti‐interleukin (IL)‐17 agents secukinumab, ixekizumab and brodalumab have been introduced more recently for moderate‐to‐severe psoriasis.1 As a consequence, possible skin adverse events as a result of their use are not so fully elucidated. Eczematous eruption (EE) has been previously reported in 5–20% of patients with various inflammatory diseases treated with anti‐TNF‐α.3 Conversely, only anecdotal cases of EE induced by anti‐IL‐12/23 or anti‐IL‐17 in patients with psoriasis have been described.
- Published
- 2019
- Full Text
- View/download PDF
17. Automatic grading of Acne vulgaris using deep learning
- Author
-
A. Melina, N. Ngo Dinh, B. Tafuri, S. De Vitis, G. Schipani, S. Nisticò, C. Cosentino, F. Amato, A. Cherubini, Melina, A., Ngo Dinh, N., Tafuri, B., De Vitis, S., Schipani, G., Nisticò, S., Cosentino, C., Amato, F., and Cherubini, A.
- Subjects
Artificial Intelligence, Deep Learning, FaceAtlas, Local Binary Pattern, Acne Vulgaris - Abstract
In this study, we trained a neural network to perform automatic grading of digital images of acne patients with reliabilities comparable or superior to those of expert physicians. A dedicated device was employed to acquire images of 479 patients belonging to three different ethnic groups. A convolutional neural network trained with features extracted from local patches extracted from the facial skin showed an accuracy of 0.85 and a correlation between manual evaluation and automatized IGA of r=0.96. This is the first work where a neural network was able to directly classify acne patients according to an ordinal scale with no human intervention and no need to count lesions.
- Published
- 2018
18. Issues in federated learning: some experiments and preliminary results.
- Author
-
Bhanbhro J, Nisticò S, and Palopoli L
- Abstract
The growing need for data privacy and security in machine learning has led to exploring novel approaches like federated learning (FL) that allow collaborative training on distributed datasets, offering a decentralized alternative to traditional data collection methods. A prime benefit of FL is its emphasis on privacy, enabling data to stay on local devices by moving models instead of data. Despite its pioneering nature, FL faces issues such as diversity in data types, model complexity, privacy concerns, and the need for efficient resource distribution. This paper illustrates an empirical analysis of these challenges within specially designed scenarios, each aimed at studying a specific problem. In particular, differently from existing literature, we isolate the issues that can arise in an FL framework to observe their nature without the interference of external factors., Competing Interests: Declarations. Competing interests: The authors declare no competing interests., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
19. INDIVIDUAL ARTICLE: Real-World Patient Cases Using Triple Lipid-Containing Cream for Cutaneous Healing Post Laser or Microneedling Radiofrequency Treatment.
- Author
-
Gold M, Andriessen A, Greiner-Krüger D, Lain E, Lee S, Suh H, McDonald C, Nisticò S, Taher Z, Wang M, and Brieva P
- Subjects
- Humans, Female, Middle Aged, Ceramides administration & dosage, Cholesterol administration & dosage, Treatment Outcome, Cosmetic Techniques, Radiofrequency Therapy methods, Fatty Acids administration & dosage, Fatty Acids chemistry, Administration, Cutaneous, Laser Therapy methods, Wound Healing drug effects, Aged, Male, Needles, Percutaneous Collagen Induction, Skin Aging drug effects, Skin Aging radiation effects, Skin Cream administration & dosage, Skin Cream chemistry, Rejuvenation
- Abstract
Lipids play an essential role in skin barrier health. With age, there is a natural reduction of physiological lipids such as fatty acids, ceramides, and cholesterol. The triple lipid restore cream is a moisturizer that contains an optimized lipid ratio for aging skin. The cream contains a 2:4:2 ratio of ceramides, cholesterol, and fatty acids that have been shown to best support aging skin. The triple lipid restore cream has been used in combination with energy-based procedures, to provide patients with comprehensive integrated skincare regimens. With limited clinical data and guidelines available in regenerative medicine, real-world cases serve as an invaluable guide for patients and dermatologists in navigating rejuvenation treatment plans. J Drugs Dermatol. 2024;23:9(Suppl 1):s3-14.
- Published
- 2024
20. Are we doing enough for controlling tuberculosis and multi-drug resistance in an epicenter of the current migration emergency (Calabria Region, Southern Italy)?
- Author
-
Rotundo S, Morrone HL, Gallo L, Dodaro S, D'Aleo F, Minchella P, Matera G, Greco F, Principe L, Trecarichi EM, Nisticò S, and Torti C
- Subjects
- Humans, Italy epidemiology, Drug Resistance, Multiple
- Published
- 2024
- Full Text
- View/download PDF
21. Use of Dupilumab in 543 Adult Patients With Moderate-to-Severe Atopic Dermatitis: A Multicenter, Retrospective Study.
- Author
-
Nettis E, Ferrucci SM, Ortoncelli M, Pellacani G, Foti C, Di Leo E, Patruno C, Rongioletti F, Argenziano G, Macchia L, Tavecchio S, Napolitano M, Ribero S, Bonzano L, Romita P, Di Bona D, Nisticò SP, Piras V, Calabrese G, Detoraki C, Carbonara M, and Fabbrocini G
- Subjects
- Adult, Antibodies, Monoclonal, Humanized, Humans, Immunoglobulin E, Retrospective Studies, Severity of Illness Index, Treatment Outcome, Conjunctivitis, Dermatitis, Atopic drug therapy
- Abstract
Background: Dupilumab has proven to be an effective treatment for patients with moderate-to-severe atopic dermatitis (AD) in clinical trials. However, real-world experience with dupilumab in a broader population is limited., Methods: The study population comprised adult patients with moderate-to-severe AD, defined as an Eczema Area Severity Index (EASI) score of 24 or higher, treated with dupilumab at 10 Italian teaching hospitals. We analyzed physician-reported outcome measures (EASI), patient-reported outcome measures (pruritus and sleep score, Dermatology Life Quality Index [DLQI]), and serological markers (IgE and eosinophil count) after 16 weeks., Results: We enrolled 543 patients with moderate-to-severe AD. Two patients (0.4%) discontinued treatment. The median (IQR) change from baseline to 16 weeks of treatment in the EASI score was -87.5 (22.0) (P<.001). The EASI-50, EASI-75, and EASI-90 response rates were 98.1%, 81.5%, and 50.8% after 16 weeks. At 16 weeks, 93.0% of the patients had achieved a 4-point or higher improvement in DLQI from baseline. During treatment with dupilumab, 12.2% of the patients developed conjunctivitis, and total IgE decreased significantly (P<.001). Interestingly, in the multivariate logistic regression model, the risk of developing dupilumab-related conjunctivitis was associated with early onset of AD (OR, 2.25; 95%CI, 1.07-4.70; P=.03) and presence of eosinophilia (OR, 1.91; 95%CI, 1.05-3.39; P=.03)., Conclusion: This is the broadest real-life study in AD patients treated with dupilumab to date. We observed more significant improvements induced by dupilumab in adult patients with moderate-to-severe AD than those reported in clinical trials.
- Published
- 2022
- Full Text
- View/download PDF
22. A Fatal Case of Tuberculosis Meningitis in Previously Health Children.
- Author
-
Colosimo M, Caruso A, Nisticò S, Minchella P, Cutruzzolà A, Tiburzi SP, Vescio V, Luciani F, Marcianò G, and Gallelli L
- Abstract
Tuberculous meningitis (TBM) is a severe form of tuberculosis. We report the development of fatal TBM in a 2-year-old previously healthy child, suggesting that TBM must be evaluated in children of all ages with non-specific symptoms of central nervous involvement because a diagnostic delay induces a negative prognosis.
- Published
- 2022
- Full Text
- View/download PDF
23. Erythema nodosum following the first dose of ChAdOx1-S nCoV-19 vaccine.
- Author
-
Cameli N, Silvestri M, Mariano M, Bennardo L, Nisticò SP, and Cristaudo A
- Subjects
- ChAdOx1 nCoV-19, Humans, SARS-CoV-2, COVID-19, Erythema Nodosum chemically induced
- Published
- 2022
- Full Text
- View/download PDF
24. Pernio-like skin lesions after the second dose of Pfizer-BioNTech COVID-19 vaccine.
- Author
-
Cameli N, Silvestri M, Mariano M, Nisticò SP, and Cristaudo A
- Subjects
- COVID-19 Vaccines, Humans, Immunization, SARS-CoV-2, COVID-19, Chilblains
- Published
- 2021
- Full Text
- View/download PDF
25. A Familial Form of Epidermolysis Bullosa Simplex Associated with a Pathogenic Variant in KRT5 .
- Author
-
Paduano F, Colao E, Grillone T, Vismara MFM, Amato R, Nisticò S, Mignogna C, Dastoli S, Fabiani F, Zucco R, Trapasso F, Perrotti N, and Iuliano R
- Subjects
- Adult, DNA genetics, Female, Humans, Male, Pedigree, Epidermolysis Bullosa Simplex genetics, Keratin-5 genetics
- Abstract
Epidermolysis bullosa simplex is a disease that belongs to a group of genodermatoses characterised by the formation of superficial bullous lesions caused by minor mechanical trauma to the skin. The skin fragility observed in the EBS is mainly caused by pathogenic variants in the KRT5 and KRT14 genes that compromise the mechanical stability of epithelial cells. By performing DNA sequencing in a female patient with EBS, we found the pathogenic variant c.967G>A (p.Val323Met) in the KRT5 gene. This variant co-segregated with EBS in the family pedigree and was transmitted in an autosomal dominant inheritance manner. This is the first report showing a familial form of EBS due to this pathogenic variant.
- Published
- 2021
- Full Text
- View/download PDF
26. Laser vs. thermal treatments of green pigment PG36: coincidence and toxicity of processes.
- Author
-
Bauer EM, Cecchetti D, Guerriero E, Nisticò S, Germinario G, Sennato S, Gontrani L, Tagliatesta P, and Carbone M
- Subjects
- Dynamic Light Scattering, Europe, Indoles, Lasers, Solid-State, Tattooing
- Abstract
Comparative laser and thermal treatments were carried out on PG36, a green phthalocyanine-based pigment, permitted in European countries where legislation on tattoo composition was issued. Prior to the treatments, PG36 was characterized by SEM imaging, EDX, IR and UV-Vis spectroscopies, revealing an excess of Si and C and O as compared to the pure halogenated Cu-phthalocyanine. Laser treatments were carried out with a Nd:YAG device applied to H
2 O and propan-2-ol dispersions. Pyrolysis and calcinations were carried out in air or under N2 flow. The outcome of the different procedures was analyzed by UV-Vis spectroscopy, GC-mass spectrometry, X-ray diffraction of the solid residues, SEM microscopy and dynamic light scattering. The comparative analysis indicated the production of different fragment compounds depending on the treatment, (pyrolysis or laser), and, to some extent, to the solvent of the dispersion, with pyrolysis generating a larger number of hazardous compounds. Hydrocarbons and cyclic siloxanes present as additives in PG36 were stable or degraded depending on the treatment. The morphology of the products is also treatment-dependent with nanoparticles < 20 nm and fibers being produced upon laser treatments only. Based on the experimental findings, the equivalence of laser and thermal treatments is evaluated.- Published
- 2021
- Full Text
- View/download PDF
27. Long-term effectiveness of dupilumab up to 52 weeks in atopic dermatitis in 253 adult patients.
- Author
-
Nettis E, Fabbrocini G, Ortoncelli M, Pellacani G, Argenziano G, Di Leo E, Patruno C, Stingeni L, Foti C, Rongioletti F, Macchia L, Tavecchio S, Napolitano M, Ribero S, Bonzano L, Calabrese G, Di Bona D, Nisticò SP, Hansel K, Romita P, Piras V, Carbonara M, Detoraki A, and Ferrucci SM
- Subjects
- Adult, Antibodies, Monoclonal, Humanized, Humans, Dermatitis, Atopic drug therapy, Eczema
- Published
- 2021
- Full Text
- View/download PDF
28. Fluorescent light energy combined with systemic isotretinoin: A 52-week follow-up evaluating efficacy and safety in treatment of moderate-severe acne.
- Author
-
Russo A, Mellergaard M, Pellacani G, Nisticò S, and Nielsen MCE
- Abstract
Fluorescent light energy therapy combined with low-dose isotretinoin or tetracycline show remarkable clinical effect on 12 cases of moderate-to-severe acne. Treatment was considered safe, well-tolerated, and highly efficacious., Competing Interests: MM and MCEN are employees of Klox Technologies., (© 2021 Klox R&D Center Guangdong Klox Biomedical Group Co., Ltd. Clinical Case Reports published by John Wiley & Sons Ltd.)
- Published
- 2021
- Full Text
- View/download PDF
29. Multicenter evaluation of xpert MTB/RIF ultra tests reporting detection of "Trace" of Mycobacterium tuberculosis DNA.
- Author
-
Mazzola E, Monte PD, Piersimoni C, Giudice AD, Camaggi A, Pedrotti C, Gurrieri F, Russo C, Farina C, Lombardi A, Viggiani P, Cenci E, Nisticò S, Rognoni V, Sala E, Cichero P, Frizzera E, Monzillo V, Morini F, Scarparo C, Borroni E, Cirillo DM, and Tortoli E
- Subjects
- DNA, Humans, Rifampin, Sensitivity and Specificity, Sputum, Antibiotics, Antitubercular therapeutic use, Mycobacterium tuberculosis genetics
- Abstract
Competing Interests: None
- Published
- 2021
- Full Text
- View/download PDF
30. Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy.
- Author
-
Talamonti M, Galluzzo M, Chiricozzi A, Quaglino P, Fabbrocini G, Gisondi P, Marzano AV, Potenza C, Conti A, Parodi A, Belloni Fortina A, Bardazzi F, Argenziano G, Rongioletti F, Stingeni L, Micali G, Loconsole F, Venturini M, Bongiorno MR, Feliciani C, Rubegni P, Amerio P, Fargnoli MC, Pigatto P, Savoia P, Nisticò SP, Giustini S, Carugno A, Cannavò SP, Rech G, Prignano F, Offidani A, Lombardo M, Zalaudek I, Bianchi L, and Peris K
- Subjects
- Chronic Disease, Emergencies, Humans, Italy, Biological Therapy, COVID-19, Psoriasis therapy
- Published
- 2020
- Full Text
- View/download PDF
31. Eczematous eruption during anti-interleukin 17 treatment of psoriasis: an emerging condition.
- Author
-
Napolitano M, Megna M, Fabbrocini G, Nisticò SP, Balato N, Dastoli S, and Patruno C
- Subjects
- Adult, Antibodies, Monoclonal, Humanized adverse effects, Drug Eruptions immunology, Eczema chemically induced, Eczema immunology, Female, Humans, Interleukin-17 immunology, Male, Middle Aged, Psoriasis immunology, Retrospective Studies, Young Adult, Dermatologic Agents adverse effects, Drug Eruptions diagnosis, Eczema diagnosis, Interleukin-17 antagonists & inhibitors, Psoriasis drug therapy
- Published
- 2019
- Full Text
- View/download PDF
32. Evaluation of the glycemic effect of methotrexate in psoriatic arthritis patients with metabolic syndrome: A pilot study.
- Author
-
Dehpouri T, Rokni GR, Narenjbon NA, Goldust M, Yamauchi PS, Wollina U, Lotti T, Kircik L, Lernia VGD, Sonthalia S, Vojvodic A, Szepietowski J, Bahadoran P, Errichetti E, Cantisani C, Atzori L, Rezaee E, Kutlubay Z, Engin B, Nisticò S, Damiani G, Conic RRZ, Goren A, Čabrijan L, and Tchernev G
- Abstract
Methotrexate (MTX) is a systemic immunosuppressant drug used for the treatment of psoriasis and psoriatic arthritis. Previous studies demonstrated a potential association between psoriasis and diabetes mellitus, obesity, atherosclerosis, hypertension, eventuating into metabolic syndrome. This study aimed at exploring the glycemic effects of MTX in psoriatic arthritis (PsA) patients. In this prospective cross-sectional study, 27 patients with PsA were evaluated. The status of PsA and presence of accompanying metabolic syndrome was determined by standard criteria and indices. Blood indicators including HbA1c, erythrocyte sedimentation rate, fasting blood sugar, total cholesterol, high-density lipoprotein, triglycerides, and C-reactive protein were examined before and 12 weeks after MTX therapy. There were no significant changes between HbA1c levels before and after MTX therapy in both genders (men: P=0.131, women: P=0.803). In addition, HbA1c levels in PsA patients with metabolic syndrome were not different before and after treatment (P=0.250). Finally, HbA1c levels did not change in PsA patients without metabolic syndrome before and after therapy (P=0.506). MTX in PsA patients does not appear to have hyperglycaemic effects in the short-term and can be safely used in patients with metabolic syndrome and diabetes., Competing Interests: Conflict of interest: the authors declare no potential conflict of interest.
- Published
- 2019
- Full Text
- View/download PDF
33. Lp-PLA 2 , a new biomarker of vascular disorders in metabolic diseases.
- Author
-
De Stefano A, Mannucci L, Tamburi F, Cardillo C, Schinzari F, Rovella V, Nisticò S, Bennardo L, Di Daniele N, and Tesauro M
- Subjects
- Humans, Risk Factors, 1-Alkyl-2-acetylglycerophosphocholine Esterase metabolism, Biomarkers metabolism, Metabolic Diseases metabolism, Vascular Diseases metabolism
- Abstract
Metabolic diseases are chronic disorders correlated to a greater risk of cardiovascular event and death. Recently, many data have sustained the biological link between microvascular dysfunction, oxidative stress, vascular inflammation, and metabolic diseases. The determination of new and specific blood biomarkers of vascular inflammation associated with obesity-related metabolic syndrome (MetS) and diabetes such as lipoprotein-associated phospholipase A
2 (Lp-PLA2 ) could be useful to identify subject with high risk of cardiovascular events. Lp-PLA2 participates by a crucial role in microvascular dysfunction and oxidative stress showing positive association with metabolic disorders. In this review, we will argue the evolving role of Lp-PLA2 in predicting cardiovascular events in metabolic disease patients.- Published
- 2019
- Full Text
- View/download PDF
34. Update of calcineurin inhibitors to treat inverse psoriasis: A systematic review.
- Author
-
Dattola A, Silvestri M, Bennardo L, Del Duca E, Longo C, Bianchi L, and Nisticò S
- Subjects
- Administration, Cutaneous, Calcineurin Inhibitors adverse effects, Dermatologic Agents adverse effects, Humans, Immunosuppressive Agents adverse effects, Psoriasis diagnosis, Psoriasis immunology, Skin immunology, Skin pathology, Tacrolimus administration & dosage, Tacrolimus adverse effects, Treatment Outcome, Calcineurin Inhibitors administration & dosage, Dermatologic Agents administration & dosage, Immunosuppressive Agents administration & dosage, Psoriasis drug therapy, Skin drug effects, Tacrolimus analogs & derivatives
- Abstract
Inverse psoriasis commonly involves skin fold areas including the axillae, perianal skin, intergluteal cleft, inframammary, genital/inguinal, abdominal, and retroauricular folds. Topical calcineurin inhibitors are indicated for the treatment of atopic dermatitis but have also been studied in the treatment of psoriasis. The object of the present study is to define the efficacy of topical calcineurin inhibitors in the treatment of psoriasis. We checked for English-vernacular articles conveyed since 1990 in PubMed, Ovid/Cochrane, and Embase using "tacrolimus," "pimecrolimus," or "topical calcineurin inhibitors," and "psoriasis" as keywords. Eight double-blind studies and seven open studies displayed the ampleness of topical tacrolimus in psoriasis. Included studies demonstrated a considerable efficacy of topical administration of tacrolimus and pimecrolimus in the treatment of psoriasis, especially for facial, genital, and intertriginous areas. The role of topical tacrolimus and pimecrolimus in the treatment of psoriasis seems to be promising as shown by the results of double-blind and open studies. Because these agents do not cause cutaneous atrophy, they have a special role in facial, genital, and intertriginous psoriatic lesions. Both agents await additional investigation to determine their roles., (© 2018 Wiley Periodicals, Inc.)
- Published
- 2018
- Full Text
- View/download PDF
35. Artificial Intelligence for the Objective Evaluation of Acne Investigator Global Assessment.
- Author
-
Melina A, Dinh NN, Tafuri B, Schipani G, Nisticò S, Cosentino C, Amato F, Thiboutot D, and Cherubini A
- Subjects
- Acne Vulgaris pathology, Adolescent, Adult, Child, Facial Dermatoses pathology, Female, Humans, Male, Middle Aged, Observer Variation, Reproducibility of Results, Young Adult, Acne Vulgaris diagnostic imaging, Artificial Intelligence, Facial Dermatoses diagnostic imaging, Image Interpretation, Computer-Assisted, Severity of Illness Index
- Abstract
Introduction: The evaluation of Acne using ordinal scales reflects the clinical perception of severity but has shown low reproducibility both intra- and inter-rater. In this study, we investigated if Artificial Intelligence trained on images of Acne patients could perform acne grading with high accuracy and reliabilities superior to those of expert physicians., Methods: 479 patients with acne grading ranging from clear to severe and sampled from three ethnic groups participated in this study. Multi-polarization images of facial skin of each patient were acquired from five different angles using the visible spectrum. An Artificial Intelligence was trained using the acquired images to output automatically a measure of Acne severity in the 0-4 numerical range of the Investigator Global Assessment (IGA)., Results: The Artificial Intelligence recognized the IGA of a patient with an accuracy of 0.854 and a correlation between manual and automatized evaluation of r=0.958 (P less than .001)., Discussion: This is the first work where an Artificial Intelligence was able to directly classify acne patients according to an IGA ordinal scale with high accuracy, no human intervention and no need to count lesions. J Drugs Dermatol. 2018;17(9):1006-1009.
- Published
- 2018
36. Cost-efficacy analysis of 3% diclofenac sodium, ingenol mebutate, and 3.75% imiquimod in the treatment of actinic keratosis.
- Author
-
Nisticò S, Del Duca E, Torchia V, Gliozzi M, Bottoni U, and Muscoli C
- Subjects
- Adjuvants, Immunologic administration & dosage, Adjuvants, Immunologic economics, Aminoquinolines administration & dosage, Anti-Inflammatory Agents, Non-Steroidal administration & dosage, Anti-Inflammatory Agents, Non-Steroidal economics, Clinical Trials, Phase III as Topic economics, Decision Trees, Diclofenac administration & dosage, Diterpenes administration & dosage, Drug Compounding, Humans, Imiquimod, Multicenter Studies as Topic economics, Randomized Controlled Trials as Topic economics, Treatment Outcome, Aminoquinolines economics, Cost-Benefit Analysis methods, Diclofenac economics, Diterpenes economics, Keratosis, Actinic drug therapy, Keratosis, Actinic economics
- Abstract
Actinic keratosis (AK) is a clinical condition characterized by keratinocytic dysplastic lesions of the epidermis, affecting individuals chronically exposed to sunlight. Topical therapies allow the treatment of a whole area of affected skin and currently include diclofenac sodium gel, 5-fluorouracil cream, 5-fluorouracil and acetylsalicylic acid solution, imiquimod cream, and ingenol mebutate gel. Due to the comparable efficacy of 3% diclofenac, ingenol mebutate, and 3.75% imiquimod in treating AK multiple lesions, a pharmacoeconomic evaluation of cost-effectiveness of the three treatments was needed. A cost-efficacy analysis comparing 3% diclofenac sodium with ingenol mebutate and 3.75% imiquimod was performed. In this analysis, efficacy data were combined with quality-of-life measurement derived from previous studies as well as the costs associated with the management of these lesions in Italy. Patients' demographics and clinical characteristics were assumed to reflect those from the clinical studies considered.
- Published
- 2018
- Full Text
- View/download PDF
37. Six years genotype distribution of Human Papillomavirus in Calabria Region, Southern Italy: a retrospective study.
- Author
-
Galati L, Peronace C, Fiorillo MT, Masciari R, Giraldi C, Nisticò S, Minchella P, Maiolo V, Barreca GS, Marascio N, Lamberti AG, Giancotti A, Lepore MG, Greco F, Mauro MV, Borelli A, Bocchiaro GL, Surace G, Liberto MC, and Focà A
- Abstract
Background: Although analysis of the Human papillomavirus (HPV) genotype spread in a particular area has a crucial impact on public health and prevention programmes, there is a lack of epidemiological data regarding HPV in the Calabria region of Italy. We therefore update information on HPV age/genotype distribution by retrospectively analysing a cohort of women, with and without cervical lesions, living in Calabria, who underwent HPV DNA testing; moreover, we also evaluated HPV age/genotype distribution in a subset of patients with cervical lesions., Methods: Cervical scrape specimens obtained from 9590 women (age range 20-75 years) from January 2010 to December 2015 were tested for HPV DNA. Viral types were genotyped by Linear Array HPV Genotyping® test (Roche, USA) at the Clinical Microbiology Operative Unit of six hospitals located in four provinces of the Calabria region. Cervical scrape specimens were also used to perform Pap smears for cytological analysis in a subset of 405 women; cytological classification of the samples was performed according to the Bethesda classification system., Results: A total of 2974 women (31%) (C.I. 95% 30.09-31.94) were found to be HPV DNA positive for at least one (57.3%) or several (42.7%) HPV genotypes. Of single genotype HPV infections, 46.5% and 36.4 % were classed as high-risk (HR, Group 1) and low-risk (LR, Group 3) respectively, while 16.9% were classed as probably/possibly carcinogenic and 0.2% undetermined risk. Stratified by age, total HPV distribution, showed the highest prevalence within the range 30-39 years (37.2%), while single genotype infection distribution displayed a peak in women from the age range 20-29 years (37.5%). The most common high-risk HPV type was HPV 16 (19.1%), followed by HPV 31 (9.1%)., Conclusions: We provide epidemiological data on HPV age/genotype distribution in women living in the Calabria region with or without cytological abnormalities, further to the enhancement of HPV screening/prevention programmes for the local population.
- Published
- 2017
- Full Text
- View/download PDF
38. Long-Pulsed 1064-nm Nd:YAG Laser for the Treatment of Onychomycosis.
- Author
-
Piccolo D, Kostaki D, Del Duca E, Cannarozzo G, Sannino M, and Nisticò S
- Subjects
- Adult, Aged, Cohort Studies, Dermoscopy methods, Female, Follow-Up Studies, Foot Dermatoses diagnosis, Humans, Male, Middle Aged, Onychomycosis diagnosis, Patient Satisfaction statistics & numerical data, Severity of Illness Index, Treatment Outcome, Young Adult, Foot Dermatoses radiotherapy, Lasers, Solid-State therapeutic use, Low-Level Light Therapy methods, Onychomycosis radiotherapy
- Abstract
Objective: The aim of this study is to evaluate the efficacy of long-pulsed 1064-nm Nd:YAG laser in penetrating tissue and targeting the fungal overgrowth in the nail plate., Background: Onychomycosis is the most frequent nail disorder. Current treatments include oral and topical antifungal agents, photodynamic therapy, and surgical approaches such as mechanical, chemical, or surgical nail avulsion. Moreover, the use of lasers to treat nail diseases has been approved in the United States by the Food and Drug Administration (FDA). Wide literature has been produced to assess the effectiveness of these devices, but, because the opposing results emerging from current studies, more data are still needed on the long-lasting efficacy and safety of this procedure., Methods: Twenty consecutive, unselected patients were enrolled in the study and treated, at intervals of 1 week, for a total of four sessions, using a long-pulsed 1064-nm Nd:YAG laser. In each session, three passages across each nail plate were performed with 1-min pause between each passage. A special lens for dermatoscopy, connected to a digital camera, was used for dermoscopic images., Results: In fourteen patients (70%; 12F; 3M), excellent results were obtained with an important reduction of chromonychia, onycholysis, opacity, longitudinal striae, and jagged proximal edge. Better results were observed in severe cases in the 2-month follow-up visit., Conclusions: Data for treating nail onychomycosis with laser and light therapy seem to be positive. The promising results of our study identify long-pulsed 1064-nm Nd:YAG laser as a possible alternative option for the treatment of onychomycosis. However, increasing subject data, improving study methodology, and output parameters may become an important next step of study in the treatment of nail onychomycosis.
- Published
- 2017
- Full Text
- View/download PDF
39. Nonconventional Use of Flash-Lamp Pulsed-Dye Laser in Dermatology.
- Author
-
Nisticò S, Campolmi P, Moretti S, Del Duca E, Bruscino N, Conti R, Bassi A, and Cannarozzo G
- Subjects
- Adolescent, Adult, Aged, Child, Female, Humans, Male, Middle Aged, Treatment Outcome, Young Adult, Lasers, Dye therapeutic use, Lighting methods, Low-Level Light Therapy methods, Skin Diseases, Vascular pathology, Skin Diseases, Vascular radiotherapy
- Abstract
Flash-lamp pulsed-dye laser (FPDL) is a nonablative technology, typically used in vascular malformation therapy due to its specificity for hemoglobin. FPDL treatments were performed in a large group of patients with persistent and/or recalcitrant different dermatological lesions with cutaneous microvessel involvement. In particular, 149 patients (73 males and 76 females) were treated. They were affected by the following dermatological disorders: angiokeratoma circumscriptum, genital and extragenital viral warts, striae rubrae, basal cell carcinoma, Kaposi's sarcoma, angiolymphoid hyperplasia, and Jessner-Kanof disease. They all underwent various laser sessions. 89 patients (59.7%) achieved excellent clearance, 32 patients (21.4%) achieved good-moderate clearance, 19 patients (12.7%) obtained slight clearance, and 9 subjects (6.1%) had low or no removal of their lesion. In all cases, FPDL was found to be a safe and effective treatment for the abovementioned dermatological lesions in which skin microvessels play a role in pathogenesis or development. Further and single-indication studies, however, are required to assess a standardized and reproducible method for applying this technology to "off-label" indications.
- Published
- 2016
- Full Text
- View/download PDF
40. TELOMERE AND TELOMERASE MODULATION BY BERGAMOT POLYPHENOLIC FRACTION IN EXPERIMENTAL PHOTOAGEING IN HUMAN KERATINOCYTES.
- Author
-
Nisticò S, Ehrlich J, Gliozzi M, Maiuolo J, Del Duca E, Muscoli C, and Mollace V
- Subjects
- Cell Line, Transformed, Humans, Keratinocytes pathology, Oxidative Stress drug effects, Oxidative Stress radiation effects, Polyphenols chemistry, Citrus chemistry, Keratinocytes metabolism, Polyphenols pharmacology, Skin Aging drug effects, Skin Aging radiation effects, Telomerase metabolism, Telomere metabolism, Ultraviolet Rays adverse effects
- Abstract
Photoageing represents the addition of extrinsic chronic ultraviolet radiation-induced damage on intrinsic ageing and accounts for most age-associated changes in skin appearance. In this study, we evaluated the effect of 38% BPF, a highly concentrated extract of the bergamot fruit (Citrus bergamia) on UVB-induced photoageing by examining inflammatory cytokine expression, telomere length/telomerase alterations and cellular viability in human immortalized HaCaT keratinocytes. Our results suggest that 38% BPF protects HaCaT cells against UVB-induced oxidative stress and markers of photoageing in a dose-dependent manner and could be a useful supplement in skin care products. Together with antioxidant properties, BPF, a highly concentrated extract of the bergamot fruit, appears to modulate basic cellular signal transduction pathways leading to anti-proliferative, anti-aging and immune modulating responses.
- Published
- 2015
41. Professional Acquisition of M. bovis in Calabria Region (Southern Italy): A Challenging Case of Osteomyelitis in a Migrant Patient from Bulgaria.
- Author
-
Quirino A, Torti C, Strazzulla A, Nisticò S, Galati L, Barreca GS, Lamberti AG, Berardelli G, Pacciarini M, Gasparini G, Pisani V, Gambardella A, Liberto MC, and Focà A
- Abstract
We report herein the first case of a coinfection with Brucella spp., M. bovis, and Enterobacter cloacae in a butcher who moved from Bulgaria to Italy. Molecular typing suggested professional acquisition of M. bovis in Italy. So, surveillance and preventive measures need to be implemented.
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.